GlobeNewswire: Orchard Therapeutics Contains the last 10 of 19 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T13:18:21ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/01/22/1703283/0/en/Orchard-Announces-Publication-by-San-Raffaele-Telethon-Institute-for-Gene-Therapy-of-OTL-300-Clinical-Data-for-the-Treatment-of-Transfusion-Dependent-Beta-Thalassemia-in-Nature-Med.html?f=22&fvtc=4&fvtv=47107Orchard Announces Publication by San Raffaele-Telethon Institute for Gene Therapy of OTL-300 Clinical Data for the Treatment of Transfusion-Dependent Beta-Thalassemia in Nature Medicine2019-01-22T12:30:00Z<![CDATA[Publication Highlights Encouraging Evidence of OTL-300’s Safety and Efficacy in Transfusion-Dependent Beta-Thalassemia Patients Publication Highlights Encouraging Evidence of OTL-300’s Safety and Efficacy in Transfusion-Dependent Beta-Thalassemia Patients]]>https://www.globenewswire.com/news-release/2019/01/07/1681213/0/en/Orchard-Therapeutics-Highlights-Recent-Accomplishments-and-2019-Strategic-Priorities-as-a-Global-Leader-in-Gene-Therapy.html?f=22&fvtc=4&fvtv=47107Orchard Therapeutics Highlights Recent Accomplishments and 2019 Strategic Priorities as a Global Leader in Gene Therapy2019-01-07T13:00:00Z<![CDATA[Preparing Three Lead Programs for MLD, ADA-SCID and WAS for Regulatory Filings Over the Next Three Years]]>https://www.globenewswire.com/news-release/2019/01/02/1679789/0/en/Orchard-Therapeutics-to-Present-at-the-37th-Annual-J-P-Morgan-Healthcare-Conference-on-January-9-2019.html?f=22&fvtc=4&fvtv=47107Orchard Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 20192019-01-02T21:01:00Z<![CDATA[BOSTON and LONDON, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that the company is scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019 at 3:00 p.m. PST.]]>https://www.globenewswire.com/news-release/2018/12/14/1667236/0/en/Orchard-Therapeutics-and-SIRION-Biotech-Announce-Licensing-Agreement-to-Enhance-Gene-Therapy-Manufacturing-Efficiency.html?f=22&fvtc=4&fvtv=47107Orchard Therapeutics and SIRION Biotech Announce Licensing Agreement to Enhance Gene Therapy Manufacturing Efficiency2018-12-14T12:30:00Z<![CDATA[BOSTON and LONDON and MARTINSRIED, Germany, Dec. 14, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, and SIRION Biotech GmbH today announced the entry into a license agreement, pursuant to which Orchard has licensed SIRION’s LentiBOOST™ technology to enhance manufacturing efficiency for certain of Orchard’s ex vivo autologous hematopoietic stem cell gene therapy drug candidates.]]>https://www.globenewswire.com/news-release/2018/12/13/1666537/0/en/Orchard-Therapeutics-Announces-the-Build-out-of-New-Gene-Therapy-Manufacturing-Facility-in-California.html?f=22&fvtc=4&fvtv=47107Orchard Therapeutics Announces the Build-out of New Gene Therapy Manufacturing Facility in California2018-12-13T12:30:00Z<![CDATA[New facility expected to create more than 100 new jobs, supporting extensive gene therapy pipeline]]>https://www.globenewswire.com/news-release/2018/12/05/1662324/0/en/Donald-B-Kohn-MD-Orchard-Therapeutics-Scientific-Advisory-Board-Member-Presents-Clinical-Proof-of-Concept-Data-for-OTL-102-Gene-Therapy-for-the-Treatment-of-Patients-with-X-CGD-at-.html?f=22&fvtc=4&fvtv=47107Donald B. Kohn, MD, Orchard Therapeutics Scientific Advisory Board Member, Presents Clinical Proof-of-Concept Data for OTL-102 Gene Therapy for the Treatment of Patients with X-CGD at the Presidential Symposium at the 2018 ASH Annual Meeting2018-12-05T12:30:00Z<![CDATA[First demonstration of potential gene therapy treatment in this population leading to sustained levels of functioning neutrophils after 12 months First demonstration of potential gene therapy treatment in this population leading to sustained levels of functioning neutrophils after 12 months]]>https://www.globenewswire.com/news-release/2018/11/08/1647884/0/en/Orchard-Therapeutics-Strengthens-Global-Commercial-Leadership-Team-with-Appointments-of-Heads-of-US-and-EMEA-Region-Commercial-Operations.html?f=22&fvtc=4&fvtv=47107Orchard Therapeutics Strengthens Global Commercial Leadership Team with Appointments of Heads of US and EMEA Region Commercial Operations2018-11-08T12:30:00Z<![CDATA[Commercial team preparing for potential gene therapy launches]]>https://www.globenewswire.com/news-release/2018/11/05/1644911/0/en/Orchard-Therapeutics-Announces-Closing-of-225-Million-Initial-Public-Offering-Including-the-Partial-Exercise-of-Underwriters-Option.html?f=22&fvtc=4&fvtv=47107Orchard Therapeutics Announces Closing of $225 Million Initial Public Offering, Including the Partial Exercise of Underwriters’ Option2018-11-05T12:00:00Z<![CDATA[BOSTON and LONDON, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics plc (Nasdaq: ORTX), a biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies, today announced the closing of its initial public offering of 16,103,572 American Depositary Shares (“ADSs”), each representing an ordinary share at an initial public offering price of $14.00 per share. The gross proceeds from the offering were $225.5 million before deducting underwriting commissions and estimated offering expenses. This includes the partial exercise by the underwriters of their option to purchase up to 1,817,857 additional ADSs from Orchard at the initial public offering price, less underwriting discounts and commissions. Each of the ADSs in the offering were offered by Orchard Therapeutics. The ADSs commenced trading on The Nasdaq Global Select Market on October 31, 2018 under the ticker symbol “ORTX.”]]>https://www.globenewswire.com/news-release/2018/10/31/1639840/0/en/Orchard-Therapeutics-Announces-Pricing-of-Initial-Public-Offering.html?f=22&fvtc=4&fvtv=47107Orchard Therapeutics Announces Pricing of Initial Public Offering2018-10-31T02:21:10Z<![CDATA[BOSTON and LONDON, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics plc (Nasdaq: ORTX), a biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies, today announced the pricing of its initial public offering in the United States of 14,285,715 American Depositary Shares (“ADSs”) representing 14,285,715 ordinary shares at an initial public offering price of $14.00 per ADS, before underwriting discounts and commissions. In addition, Orchard has granted the underwriters a 30-day option to purchase up to an additional 2,142,857 ADSs at the initial public offering price, less the underwriting discounts and commissions. Orchard’s ADSs are expected to begin trading on The Nasdaq Global Select Market on October 31, 2018, under the ticker symbol “ORTX.” Each of the ADSs are being offered by Orchard. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Orchard, are expected to be $200.00 million, excluding any exercise of the underwriters’ option to purchase additional ADSs. The offering is expected to close on November 2, 2018, subject to the satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2018/10/04/1601340/0/en/Orchard-Therapeutics-Receives-EMA-PRIME-Designation-for-OTL-300-an-Investigational-Lentiviral-Gene-Therapy-for-the-Treatment-of-Transfusion-Dependent-Beta-Thalassemia.html?f=22&fvtc=4&fvtv=47107Orchard Therapeutics Receives EMA PRIME Designation for OTL-300, an Investigational Lentiviral Gene Therapy for the Treatment of Transfusion-Dependent Beta-Thalassemia2018-10-04T12:00:00Z<![CDATA[BOSTON and LONDON, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a leading commercial-stage biotech company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to OTL-300, an investigational autologous ex vivo lentiviral gene therapy for the treatment of transfusion-dependent beta-thalassemia (TDBT), the most severe form of beta-thalassemia.]]>